Hui Jian

Hui Jian

Auto-generated profile, based on publicly available information

Hui Jian

CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2022 in Cancer Gene Therapy
Verified
Journal Article
Closed access
PDF file
Yun ZhangYun Zhang
Yun Zhang
ZLZhe Liu
Zhe Liu
XWXueliang Wang
Xueliang Wang
HJHui Jian
Hui Jian
HXHaihan Xiao
Haihan Xiao
Tingyi WenTingyi Wen
Tingyi Wen

1 March 2022 in Acta Biomaterialia
Verified
Journal Article
Closed access
HJHui Jian
Hui Jian
XWXingbo Wang
Xingbo Wang
PSPanPan Song
PanPan Song
XWXiaqing Wu
Xiaqing Wu
RZRunxiao Zheng
Runxiao Zheng
Haiyuan ZhangHaiyuan Zhang
Haiyuan Zhang

13 May 2022 in Nanoscale
Verified
Journal Article
Closed access
PDF file
HJHui Jian
Hui Jian
Yun ZhangYun Zhang
Yun Zhang
JWJunyue Wang
Junyue Wang
ZCZhenxiang Chen
Zhenxiang Chen
Tingyi WenTingyi Wen
Tingyi Wen
The reprogrammed amino acid metabolism maintains the powerful antioxidant defense and DNA damage repair capacity of cancer cells, which could promote their escape from reactive oxygen species (ROS)-induced damage and inevitably diminish the efficacy of ROS-based therapies. Herein, we propose a strategy to enhance the effect of chemodynamic therapy (CDT) via glutaminolysis-targeted inhibition for cancer cells dependent on abnormal glutamine metabolism. To screen optimum drugs targeting glutamine metabolism, transcriptomic analysis is performed to identify predictive biomarkers. Eventually, telaglenastat (CB-839) is used to block mitochondrial glutaminase 1 (GLS 1) in basal-like breast cancer and loaded into the developed iron-doped zeolitic imidazolate frameworks (ZIF(Fe) NPs) to form ZIF(Fe)&CB nanoparticles, which are able to co-deliver Fe2+ and CB-839 into the tumor. CB-839 induced-glutaminolysis inhibition not only reduces intracellular antioxidants (glutathione, taurine) to amplify Fe2+-induced oxidative stress, but also decreases nucleotide pools (e.g., adenosine, dihydroorotate) to incur the deficiency of building blocks for DNA damage repair, thereby promoting the cell-killing effect of CDT. In vivo assessments further confirm the enhanced anticancer performance and good biocompatibility of ZIF(Fe)&CB nanoparticles. This study provides a promising strategy for the development and improvement of ROS-based anticancer nanosystems.